Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...
Hosted on MSN3h
Novel Drug Eases Disease Activity in DermatomyositisCurrent treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
ScreenRant on MSN22h
Stephen King Just Confirmed His Best Book Of The 2020s & I Couldn't Be More ExcitedA fter a few months of speculation, Stephen King has finally confirmed he's working on a book that will be his best one of ...
Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
In “Open Socrates,” the scholar Agnes Callard argues that the ancient Greek philosopher offers a blueprint for an ethical ...
There’s more than one ghost in the machine in,” Nnedi Okorafor’s new sci-fi-adjacent novel finely attuned to our age of AI ...
The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...
The Writers Guild of America announced its feature-film nominations on Wednesday, furthering the awards-season momentum ...
Read here for more on the potential of RCUS's combination therapies for various cancers, with promising Phase 3 trials and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback